Roivant Sciences (ROIV)

[aries4747]

Two ROIV executives sit on ABUS Board of Directors

Frank Torti MD
Chairman
Dr. Torti has served as Chairperson of Arbutus’s board of directors since November 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc. (RSI) since January 2020. In this capacity he serves as Chairperson of the boards of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. He previously served as Vant Investment Chair of RSI, from August 2018 to December 2019.

Eric Venker M.D., Pharm.D.
Independent Director
Dr. Venker has served on Arbutus’s board of directors since February 2020. Dr. Venker has served as Chief Operating Officer of Roivant Sciences, Inc. (RSI) since November 2018. From October 2017 to October 2018, he served as Chief of Staff to RSI’s Chief Executive Officer, and from 2014 to 2015 as an Analyst at RSI.